



Ralph Schiess

Kontakt

Ralph Schiess

Publikationen (8)

Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen Sommer S. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies. *BJU Int* 2018

Sajic T, Claassen M, Gillessen Sommer S, Omlin A, Malander S, Niméus E, Friedrich B, Blattmann P, Chen R, Brentnall T, Pan S, Sethi A, Hüttenhain R, Schiess R, Williams E, Surinova S, Arvaniti E, Liu Y, Aebersold R. Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. *Cell Rep* 2018; 23:2819–2831.e5.

Endt K, Joos T, Gillessen Sommer S, Steuber T, Engeler D, Rainisio M, Guenther A, Tennstedt P, Athanasiou A, Omlin A, Goepfert J, Schiess R. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. *PLoS one* 2017; 12:e0181557.

Rothermundt C, Cathomas R, Rüschoff J, Schiess R, Endt K, Lui L, Pollak M, Bärtschi D, Strebel R, Winterhalder R, Templeton A, Hayoz S, Gillessen Sommer S. Metformin in chemotherapy-naïve castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). *Eur Urol* 2014; 66:468–74.

Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naïve patients with castration-resistant prostate cancer (SAKK 08/08). *Eur Urol* 2013; 64:150–8.

Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clin Cancer Res* 2012; 18:6049–57.

Kaelin M, Krek W, Aebersold R, Cerny T, Templeton A, Wild P, Powles T, Fankhauser N, Schiess R, Cima I, Gillessen Sommer S. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. *Eur Urol* 2011; 60:1235–43.

Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. *Proc Natl Acad Sci USA* 2011; 108:3342–7.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch